Compare Stocks

Princeton Bancorp, Inc. operates as the bank holding company for The Bank of Princeton that provides various banking products and services. It accepts various deposit products, including checking, savings, attorney trust, and money market accounts, as well as certificates of deposit. The company also offers traditional retail banking services, one-to-four-family residential mortgage loans, multi-family and commercial mortgage loans, construction loans, commercial business loan, and consumer loans, as well as home equity loans, lines of credit, industrial, and residential first-lien mortgage loans. In addition, it provides debit and credit cards, and money orders, direct deposit, automated teller machines, cashier's checks, safe deposit boxes, online banking, wire transfers, night depository, remote deposit capture, bank-by-mail, online, and automated telephone banking services, as well as payroll-related services and merchant credit card processing services. Further, the company offers full on-line statements, on-line bill payment, account inquiries, mobile banking, transaction histories and details, and account-to-account transfer services. Princeton Bancorp, Inc. was incorporated in 2007 and is headquartered in Princeton, New Jersey.

Countrywide plc, together with its subsidiaries, provides residential estate agency and property services in the United Kingdom. It operates through Sales and Lettings, Financial Services, and Business to Business (B2B) segments. The company offers surveying services, including valuation panel management services, residential valuations, and surveys for mortgage lenders; provides corporate, emergency, commercial, and social relocation services; estate, leasehold and block management services; and sells residential, commercial, industrial, and agricultural properties, as well as land through public auction. It also provides integrated property services; conveyancing services, such as freehold and leasehold, remortgage, and separate legal representation; and residential property asset management services. In addition, the company is involved in the residential development and investment activities; and provision of single mortgage brokerage services, as well as home and personal insurance. It serves residential and commercial property markets. Countrywide plc was founded in 1986 and is headquartered in Milton Keynes, the United Kingdom. As of March 8, 2021, Countrywide plc operates as a subsidiary of Connells Limited.

Integra Resources Corp. is a mineral resources company, which engages in the acquisition, exploration, and development of mineral properties. It holds interest in DeLamar Deposit and Florida Mountain Deposit projects. The company was founded on April 15, 1997 and is headquartered in Vancouver, Canada.

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.